To see the impact of combination therapy on different tumors and lymphomas, we categorized them based on six major tumor-associated antigens: mesothelin, disialoganglioside GD-2, CD-19, CD-22, CD-133, and CD-30, which are present in various tumors (27–32). This evidence concerns the gene PROM1 and neoplasm.